TransMedics Group (NASDAQ:TMDX) Shares Gap Down – Should You Sell?

TransMedics Group, Inc. (NASDAQ:TMDX)’s share price gapped down before the market opened on Friday . The stock had previously closed at $72.55, but opened at $62.93. TransMedics Group shares last traded at $63.16, with a volume of 1,848,804 shares changing hands.

Analyst Ratings Changes

A number of brokerages have weighed in on TMDX. Oppenheimer reissued an “outperform” rating and issued a $125.00 target price on shares of TransMedics Group in a research report on Tuesday, December 3rd. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. Piper Sandler decreased their target price on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a research note on Wednesday, December 11th. Finally, TD Cowen reduced their price objective on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, TransMedics Group presently has a consensus rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Trading Down 13.7 %

The stock has a market capitalization of $2.10 billion, a PE ratio of 66.61 and a beta of 2.12. The stock has a 50-day moving average price of $74.25 and a two-hundred day moving average price of $121.63. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. During the same period in the prior year, the company posted ($0.12) EPS. The company’s quarterly revenue was up 63.7% on a year-over-year basis. As a group, equities analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the transaction, the director now directly owns 732 shares in the company, valued at $61,158.60. This represents a 90.22 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the sale, the insider now directly owns 20,843 shares of the company’s stock, valued at $1,800,835.20. The trade was a 4.94 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 16,459 shares of company stock worth $1,802,244. Insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

A number of large investors have recently modified their holdings of the business. USA Financial Formulas purchased a new position in TransMedics Group during the third quarter worth approximately $55,000. Quarry LP boosted its position in shares of TransMedics Group by 557.1% during the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after acquiring an additional 312 shares during the last quarter. National Bank of Canada FI grew its holdings in shares of TransMedics Group by 174.7% in the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after purchasing an additional 262 shares during the period. Farther Finance Advisors LLC increased its position in TransMedics Group by 187.0% during the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock worth $76,000 after purchasing an additional 316 shares during the last quarter. Finally, Rakuten Securities Inc. acquired a new stake in shares of TransMedics Group during the 3rd quarter worth approximately $126,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.